KRAS and cancer: This was achieved by amplifying mutant DNA isolated from a human cancer cell line recovered from clinical samples, using electrochemical techniques and SPCEs to detect a clinically relevant mutation, comparing the signal change from DNA hybridisation experiments involving amplified KRAS mutant samples and amplified wild-type KRAS samples, varying concentration of amplified products to determine concentration effects and establishing a limit of detection for the DNA amplification reaction.